NeuBase Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2021
December 23, 2021 at 04:06 pm EST
NeuBase Therapeutics, Inc. reported earnings results for the full year ended September 30, 2021. For the full year, the company reported net loss was USD 25.41 million compared to USD 17.38 million a year ago. Basic loss per share from continuing operations was USD 0.93 compared to USD 0.89 a year ago. Diluted loss per share from continuing operations was USD 0.93 compared to USD 0.89 a year ago.